JMP and Piper Jaffray are the joint bookrunning managers for offering
By Devika Patel
Knoxville, Tenn., July 24 – Intersect ENT, Inc. said it priced its $55 million initial public offering of stock with an $8.25 million greenshoe.
The company will sell 5 million common shares at $11.00 apiece.
J.P. Morgan Securities LLC and Piper Jaffray & Co. are the joint bookrunning managers.
Settlement is expected July 29.
Proceeds will be used for clinical trials, development, working capital and other general corporate purposes.
The drug-delivery device company is based in Menlo Park, Calif. It intends to list its common stock on the Nasdaq under the symbol “XENT.”
| Issuer: | Intersect ENT, Inc.
|
| Issue: | Common stock
|
| Amount: | $55 million
|
| Greenshoe: | $8.25 million
|
| Shares: | 5 million
|
| Price: | $11.00
|
| Warrants: | No
|
| Bookrunners: | J.P. Morgan Securities LLC and Piper Jaffray & Co.
|
| Co-managers: | Leerink Partners and Wedbush PacGrow Life Sciences
|
| Pricing date: | July 24
|
| Settlement date: | July 29
|
| Stock exchange: | Nasdaq: XENT
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
